Press Releases

To access BeiGene's global press releases

Click here

BeiGene Canada Invests 500K To Fund Innovative Cancer Research

Announcement Made in Collaboration with the New Brunswick Minister of Health, ResearchNB, and the Atlantic Cancer Research Institute. MONCTON, NB, Aug. 21, 2023 /CNW/ – BeiGene Canada, the country affiliate of global biotechnology company BeiGene, specialized in the discovery and development of novel, affordable, and accessible oncology medications, announced today the launch of a partnership […]

Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adult

TORONTO, May 30, 2023 /CNW/ – BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that (PR) BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL). This is the fourth Canadian approval for BRUKINSA, following authorizations for: […]

Quebec becomes first province to cover BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s macroglobulinemia

First and only BTK inhibitor to be granted provincial formulary approval TORONTO, Feb. 6, 2023 /CNW/ – BeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton’s tyrosine kinase (BTK), for the treatment of adult […]

BeiGene Canada Named a Great Place to Work®

MISSISSAUGA, ON, Jan. 9, 2023 /CNW/ – BeiGene Canada, a subsidiary of global pharmaceutical company BeiGene has been recognized as a Great Place to Work® following a thorough, independent analysis conducted by the Great Place to Work® Institute Canada. BeiGene joins leading Canadian organizations whose employees have created and excelled at fostering exemplary workplaces.  “We are extremely proud to have been […]

BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia

BRUKINSA is now commercially available in Canada following approval in March. Canadian patients now have access to the myBeiGene® patient support program. MISSISSAUGA, Ontario–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA® (zanubrutinib) in Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). […]